GU Ventures
Since 1995, GU Ventures has supported projects and companies spawned by the University of Gothenburg. The company is wholly owned by the Swedish state and managed since 1998 by the University of Gothenburg. They are located at Erik Dahlbergsgatan at Vasaplatsen in Gothenburg on the same street as the University of Gothenburg Research and Innovation Office, Företagarna and Nyföretagarcentrumand, within walking distance to the University of Gothenburg's main building and several faculties. In close collaboration with the Research and Innovation Office at GU, Innovationskontor Väst and the Gothenburg innovation system with partners such as Encubator, Chalmers Innovation, Framtidens Företag and Sahlgrenska Science Park, they contribute to the renewal of industry through commercialization of research and expertise. All business ideas must have commercial viability and solve a problem for a customer. The companies shall strive to become profitable and successful by satisfying a market need. The aim is to create successful businesses to generate good knowledge- and capital repayment to the University of Gothenburg. Furthermore, they intend to increase growth in the region and contribute to the utilization of research for a better life and society with new products and services.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Profundus Imaging is developed a new fundus camera that could be used to provide researchers and clinicians with a tool that can visualize currently subclinical changes of retinal disease. The camera is built on so-called Adaptive Optics, a technology that is normally used in terrestrial space telescopes and was developed due to a need for improved resolution in retinal imaging and offers 7-10 times higher resolution than conventional instruments over a considerably larger imaging area than competing concepts.
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal. OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.
Mimbly saves water(s) by creating innovative solutions for water saving and microplastic capturing.
Cereno Scientific AB develops a new innovative treatment for patients with increased risk of blood clotting, based on the company's newly patented research findings. Cereno Scientific AB develops drugs that normalize the body's own defense system against blood clots for the treatment of complications in cardiovascular diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.